NTR

Bench-Top Centrifuges--Basic Tools for the Small Lab

No matter how elementary or advanced, every clinical laboratory possesses one essential devicea centrifuge. It may be a bench-top or floor model, refrigerated or non-cooled, but this apparatus, because of its unique ability to fractionate liquid specimens by creating spin-induced high g-forces, has long been a standard tool for both diagnosis and research applications. For all this utility, t...

Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance

Both methicillin sensitive and methicillin resistant Staphylococcus aureus (MSSA, MRSA) can cause invasive and life-threatening infections such as osteomyelitis, septicemia, endocarditis, and pneumonia. Healthcare associated MRSA is of particular clinical importance because it is not only predictably cross resistant to all penicillins and cephalosporins, but is also typically resistant to mu...

Tight Glycemic Control in the ICU

The outcome of many illnesses for which patients are treated in intensive care units (ICUs) has not improved dramatically over the past decades, despite the development of high-tech monitors and sophisticated mechanical and pharmacological support of vital organ systems. Indeed, critically ill patients requiring intensive care for more than five day...

New Quality Control Systems for Every Laboratory Application

Quality Control (QC) materials and procedures are key to meeting the needs of doctors and patients by verifying accuracy and precision of analytical methods. Vendors of these systems can be a valuable resource, designing customized QC materials and protocols to help lab managers ensure that analytical error st...

Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control

According to the American Diabetes Association, the total annual economic cost of diabetes in 2002 was estimated to be $132 billion, or one out of every 10 health care dollars spent in the United States. A chronic disease with no cure, diabetes is a group of diseases (including Type 1, Type 2, and gestational) marked by...

Optimizing Quality Control Data Management

Automation continues to gain importance in modern clinical laboratories in step with increasing test consolidation, rising demands from clinicians for rapid turnaround times, and an ever-mounting shortage of licensed medical technologists. Ultimately, the laboratories that implement high-quality automation solutions are better equipped to meet these modern demands....

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m.Central European Time members of Cell Therapeutics, Inc.'s (CTI)management team will host a conference call to discuss today'sannouncement of the interim results of its phase II/III RAPID trialcomparing CHOP-R to CPOP-R, in which pixantrone is substituted fordoxor...

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

-- Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects -- CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company and A...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects CHICAGO, June 25 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company (NYSE: BMY...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trialanticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced the publication of preclinicalstudies, which demonstrate that treatment with pixantrone (BBR2778) resulted in minimal or no significant cardiotoxicity, whiledoxorubicin and mitoxantrone induced significant cardiac da...

New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range ofpatient populations, including varied ethnic groups, the elderly,and those at high risk of developing diabetes * Galvus lowers blood sugar when added to a sulfonylurea,reinforcing efficacy in combination with commonly used diabetesmedicines * Data confirm good tolerability in humans with studies showingincidence of sid...

Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting

EXETER, N.H.--(BUSINESS WIRE)--Jun 25, 2007 - BentleyPharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceuticalcompany, today announced positive clinical results in threeCompany-sponsored studies of its investigational drug, Nasulin(TM),an intranasal insulin spray. The data were presented this pastweekend at the American Diabetes Association 67th ScientificSessions in Chicago. In a pl...

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., announced today the publication of clinicaldata highlighting the ability of Glufast(R) (mitiglinide calciumhydrate) monotherapy, or combination therapy with metformin, tomanage glucose surges before and after meals. The data werepublished in the Abstract Book for the American DiabetesAssociation 67th Annual Scien...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., aprivately-held biopharmaceutical company focused on the developmentof therapeutics to treat metabolic diseases, today announced thepresentation of top line data of its phase 2a study of DIO-902, afir...

Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study

COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinicalresults from the first of five phase 3 studies with liraglutide -the once-daily human GLP-1 analogue. The 26-week study is part ofthe LEAD(TM) (Liraglutide Effect and Action in Diabetes) programmeand included 581 patients with type 2 diabetes inadequatelycontrolled by two of the most widely used oral antidiabetic drugs:metfor...

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)Therapeutics, Inc. , a biopharmaceutical company focused on thetreatment of central nervous system disorders with an initial focuson obesity, today announced that the Company will present dataabout its lead obesity product candidate Contrave(TM) and itseffect on markers of cardiovascular disease (visceral fat, serumcholestero...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

Pharmacokinetic and Safety Profile of the Intramuscular Formulationof Peramivir Supports Further Evaluation as Treatment for AcuteInfluenza BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ --BioCryst Pharmaceuticals, Inc. presented results from two Phase Iclinical studies of an intramuscular (i.m.) formulation ofperamivir at the Options for the Control of Influenza Conference inTor...

Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

* New data from 741-patient trial show those treated withPrexige experienced significantly smaller impact on blood pressurecompared to ibuprofen[1] * Many patients with osteoarthritis also have high bloodpressure; even small changes in blood pressure can impactcardiovascular risk[2],[3] * Prexige approved in more than 50 countries and currently underreview in US for use in o...

Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

New data From 741-patient Trial Show Those Treated with LumiracoxibExperienced Significantly Smaller Impact on Blood Pressure Comparedto Ibuprofen EAST HANOVER, N.J., June 15, 2007 /PRNewswire/ -- Patients withosteoarthritis who also have controlled hypertension experienced aslight decrease in average daily blood pressure when treated withthe investigational selective COX-2 inhibitor lumi...

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Bristol-Myers Squibb Company today announced results regarding theefficacy and safety of ORENCIA(R) (abatacept) from the open-labelphase of an ongoing investigational study in children with juvenileidiopathic arthritis (JIA) who have had an inadequate response toone or more disease-modifying anti- rheumatic drugs (DMARDs), suchas m...

Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer

<p style="MARGIN: 0in 0in 0pt; LINE-HEIGHT: 150%; mso-hyphenate: none">BUDAPEST, Hungary, June, 7, 2007--A pioneering nasal spraycould stop thousands of patients with cancer from sufferingunnecessary pain; it was reported today1 at the 10th Congress ofthe European Association for Palliative Care, Budapest, 7–9June. The study investigated whether this first in class novelformulation c...

Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer Study Presented at ASCO

Safety, Efficacy and Markers Demonstrated in Combination Trial ROCKVILLE, Md., June 06, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics primarily for the treatment of cancer and inflammatorydiseases, announced the presentation of interim data from the Phase1b study with Panzem(R) NCD (2ME2 or 2-methoxyestradiol) incombination w...

Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study

Patients Using ROX-888 Required Significantly Less Morphine AfterMajor Abdominal Surgery Company On Track To File NDA In 2008 MENLO PARK, CA (June 6, 2007) – ROXROPHARMA Inc. said today that ROX-888, its novel intranasalanalgesic, rapidly and effectively eased pain and was welltolerated by patients who had undergone major abdominal surgery ina Phase 3 clinical study....

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - ElixirPharmaceuticals, Inc., announced today new preclinical dataconfirming ghrelin antagonism as a potential method for regulatingmetabolism, decreasing body weight and managing blood glucose. Thedata were presented in poster sessions during ENDO 07, TheEndocrine Society's 89th Annual Meeting, being held in Toronto,Canada. Elixir is focused...

Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - JavelinPharmaceuticals, Inc. (AMEX: JAV), a leading developer of novelproducts for pain control, today announced that its Phase 2multi-dose study of Rylomine was published in Pain Medicine, theofficial journal of The American Academy of Pain Medicine. Thearticle, entitled, "Analgesic Efficacy and Safety ofMorphine-Chitosan Nasal Solution in P...

Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study Presented at ASCO

Safety and Single-Agent Activity Support Development of Panzem(R)NCD as a Combination Therapy for Glioblastoma Multiforme ROCKVILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announces the presentation of results of a single-agent Phase 2study for Panzem(...

Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.(NASDAQ: INGN) and the Company's clinical collaborators todayreported updated Phase 2 data demonstrating a significantcorrelation between abnormal p53, tumor responses and increasedsurvival following ADVEXIN(R) therapy in patients with recurrentsquamous cell carcinoma of the head and neck. The data (Abstract#6057) were prese...

Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors

SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc.(NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN241, the Company's novel investigational mda-7/IL-24 tumorsuppressor agent, in patients with advanced solid tumors. The data (Abstract #380), which were presented today at theannual meeting of the American Society of Gene Therapy, showed thatin this 22-patie...

EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models

ROCKVILLE, Md., June 01, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announced the presentation of preclinical results for its Aurorakinase - angiogenesis inhibitor, ENMD-981693. The data werepresented during oral and poster presentations by EntreMedscientists at the 2n...

Introgen's Advexin Demonstrates Clinical Benefit in Inherited Cancer

AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007--IntrogenTherapeutics, Inc. (NASDAQ:INGN) announced today the publication ofdata describing the dramatic clinical benefit of its lead productAdvexin in a patient with a rare inherited form of cancer known asLi-Fraumeni Syndrome (LFS), a genetic disorder characterized byinherited mutations i...

Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - IntrogenTherapeutics, Inc. (NASDAQ:INGN) and the Company's clinicalcollaborators will report updated Phase 2 clinical trial resultsfor its lead cancer therapy product candidates at the upcomingannual meetings of The American Society of Clinical Oncology (ASCO)in Chicago and the American Society of Gene Therapy (ASGT) inSeattle. "We have a st...

ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007 Conference

Clear Anti-Inflammatory Activity Demonstrated Among Patients withActive Disease MOUNTAIN VIEW, Calif., May 23, 2007 /PRNewswire/ --ChemoCentryx, Inc., a clinical-stage biopharmaceutical companyfocused on discovering, developing and commercializingorally-administered therapeutics that target the chemokine system,presented data today from the company's Phase 2 clinical trial ofTraficet-EN...

Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients

Proposed Phase III Trial Has the Potential to Demonstrate an Effecton a Serious or Life Threatening Aspect of This Disease SEATTLE, May 07, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today it received fast trackdesignation from the U.S. Food and Drug Administration (FDA) forpixantrone, a novel anthracenedione, being investigated for thepotential treatment of rel...

Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist

Findings Show Compliance with Medication Instructions butUnderscore Need for Improved Patient Communication, LifestyleManagement and More Healthcare Provider Efforts to Control ElevatedBlood Pressure NEW YORK, May 19, 2007 /PRNewswire/ -- Results of a surveyconducted by Harris Interactive(R) for the Hypertension EducationFoundation (HEF) were presented at the American Society ofHypertens...

King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For 24-hour Blood Pressure Control

BRISTOL, Tenn.--(BUSINESS WIRE)--May 19, 2007 - KingPharmaceuticals, Inc. (NYSE:KG) reported today that data from itsPhase III clinical trial evaluating Altace (ramipril) 20mg and thecombination of ALTACE 20mg and hydrochlorothiazide (HCT) 25mg werepresented this weekend at the American Society of Hypertension,Inc. (ASH) Twenty-Second Annual Scientific Meeting and Exposition(ASH 2007) in Ch...

Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data

Nine out of 10 non-diabetic patients treated withExforge achieved recommended blood pressure goals[1] Additional average decrease of 20 mmHg insystolic blood pressure observed in patients taking Exforge overreductions seen with previous monotherapy[1] Nearly 70% of those with high blood pressure notat treatme...

Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron

WASHINGTON--(BUSINESS WIRE)--May 21, 2007 - Roche today announcedresults of a small study demonstrating that all patients whodiscontinued treatment with Peg-Intron(R) (peginterferon alfa-2b)and ribavirin due to adverse events within the first 12 weeks, wereable to complete 12 weeks of treatment with PEGASYS(R)(peginterferon alfa-2a) and ribavirin. Furthermore, 92 percent ofthese patients we...

Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy

Cytos Biotechnology reports positive results from placebocontrolled phase IIa study in patients suffering from house dustmite allergy SCHLIEREN (Zurich), Switzerland, May 15, 2007 - Cytos BiotechnologyAG (SWX:CYTN) reported today positive results from a multi-centreand placebo-controlled phase IIa study with different formulationsof CYT003-QbG10, an immunotherapeutic product can...